Fig. 9From: Constructing a novel mitochondrial-related gene signature for evaluating the tumor immune microenvironment and predicting survival in stomach adenocarcinomaRisk score predicts drug therapeutic benefits in STAD. Proportion of normalized IC50 value of the 60 drugs between the low-risk and high-risk groups. P values were showed as: ns not significant; *P < 0.05; **P < 0.01; ***P < 0.001Back to article page